Revenue increased 29% to $13.5 million in Q3 2025 as compared with Q3 2024
Operating income totaled $1.3 million and Adjusted EBITDA rose approximately 80% to $2.0 million in Q3 2025, as compared with Q3 2024
Remaining performance obligations increased to $65 million
FDA cleared an accelerated protocol for Deep TMS treatment of patients with major depressive disorder (MDD)
Raised midpoint of full-year 2025 Revenue and EBITDA guidance
Conference call to be held today at 8:30 AM ET
BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 11, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported third quarter 2025 financial results and provided an operational update.
Recent Financial and Operational Highlights
-- Revenue in the third quarter of 2025 increased 29% to $13.5 million,
compared to the third quarter of 2024.
-- Approximately 70% of recent customer engagements are structured as
multi-year lease agreements.
-- Currently have $65 million in remaining performance obligations from
customers under multi-year contracts.
-- Shipped a net total of 90 Deep TMS$(TM)$ systems during the third quarter
of 2025, a 43% increase compared to the same period last year. Total
installed base now stands at more than 1,600 systems.
-- Gross margin for the third quarter of 2025 was 75%, compared to 74% in
the prior year period.
-- Operating income for the third quarter of 2025 was $1.3 million, compared
with $0.3 million for the prior year period.
-- Adjusted EBITDA1 for the third quarter of 2025 increased 81% to $2.0
million, compared to $1.1 million for the third quarter of 2024.
-- Net profit for the third quarter of 2025 increased 137% to $1.6 million,
compared to $0.7 million for the third quarter of 2024.
-- As of September 30, 2025, cash, cash equivalents, and restricted cash
totaled $70.7 million.
-- The U.S. Food and Drug Administration (FDA) cleared BrainsWay's
Accelerated Deep TMS(TM) protocol for the non-invasive treatment of Major
Depressive Disorder (MDD), including patients with comorbid anxiety
symptoms.
-- The NIH has awarded a $2.5 million, five-year R01 grant to researchers at
Stanford University and the Palo Alto Veterans Institute for Research to
study the mechanism and efficacy of an accelerated Deep TMS protocol,
using BrainsWay's device for the treatment of Alcohol Use Disorder (AUD).
-- Announced four new minority equity investments in 2025, expanding
strategic presence across the mental health treatment ecosystem.
-- Announced an initial $5 million strategic investment in Neurolief Ltd., a
developer of the world's first wearable, non-invasive, multi-channel
brain neuromodulation platform for home use, with an option to acquire
the company.
Full-Year 2025 Financial Guidance
-- With results continuing to trend toward the high end of expectations and
improved visibility into the remainder of the year, the Company is
raising the midpoint and narrowing its full-year 2025 financial outlook:
including:
-- Revenues of $51 million -- $52 million, up from the previous
guidance of $50 million -- $52 million;
-- Operating income of 6% -- 7%, up from the previous guidance of 4%
-- 5%; and
-- Adjusted EBITDA of 13% -- 14%, up from the previous guidance of
12% -- 13%.
"Market dynamics continue to align in our favor as we maintained strong top-line growth and increased profitability. Our Deep TMS system drove record demand in the third quarter of 2025, with meaningful adoption among both existing and new customers. Looking ahead, we see significant opportunities to extend our leadership through new therapeutic indications, accelerated treatment protocols, and broader market adoption initiatives, including potential strategic collaboration involving complementary technologies such as the at-home solutions offered by Neurolief following our recent investment in that company" said Hadar Levy, BrainsWay's Chief Executive Officer.
"With much of our revenue derived from multi-year customer agreements, we believe we have built a solid foundation for sustainable growth. In line with this, we continue to take deliberate steps to generate long-term value for shareholders. To this end, over the past year, we have gained significant momentum with our strategic initiative to invest in high-performing mental health providers through minority equity investments. To date in 2025, we have announced four such investments and are evaluating additional opportunities. In addition to our potential as equity investors, we believe this initiative has the potential to support our core business by accelerating awareness of therapies like Deep TMS with these mental health clinics and their patients," concluded Mr. Levy.
Call and Webcast
BrainsWay's management will host a conference call on Tuesday, November 11, 2025, at 8:30 a.m. Eastern Time to discuss these results and answer questions.
Tuesday, November 11, 2025, at 8:30 AM Eastern Time:
United States: 1-877-300-8521 International: 1-412-317-6026 Israel: 1-80-921-2373 Conference ID: 10203968 Webcast: Link
The conference call will be broadcast live and will be available for replay for 30 days on the Company's website, https://investors.brainsway.com/events-and-presentations/event-calendar. Please access the Company's website at least 10 minutes ahead of the conference call to register.
Non-IFRS Financial Measures
In addition to our results determined in accordance with International Financial Reporting Standards (IFRS), including in particular operating profit and net profit, we believe that Adjusted EBITDA, a non-IFRS measure, is useful in evaluating our operating performance. We define Adjusted EBITDA as net profit adjusted for depreciation and amortization, finance income, finance expenses, income taxes, cost of share-based payments, and one-time restructuring and litigation expenses.
In addition to operating income (loss) and net income (loss), we use Adjusted EBITDA as a measure of operational efficiency. We believe that this non-IFRS financial measure is useful to investors for period-to-period comparisons of our business and in understanding and evaluating our operating results for the following reasons:
-- Adjusted EBITDA is widely used by investors and securities analysts to
measure a company's operating performance without regard to items such as
stock-based compensation expenses, depreciation and amortization, finance
expenses, income taxes, and certain one-time items such as restructuring
and litigation expenses, that can vary substantially from company to
company depending upon their financing, capital structures and the method
by which assets were acquired.
-- Our management uses Adjusted EBITDA in conjunction with IFRS financial
measures for planning purposes, including the preparation of our annual
operating budget, as a measure of operating performance and the
effectiveness of our business strategies and in communications with our
board of directors concerning our financial performance; and Adjusted
EBITDA provides consistency and comparability with our past financial
performance, facilitates period-to-period comparisons of operations, and
also facilitates comparisons with other peer companies, many of which use
similar non-IFRS or non-GAAP financial measures to supplement their IFRS
or GAAP results.
Adjusted EBITDA, however, should not be considered as an alternative to operating profit (loss) or net profit (loss) for the period and may not be indicative of the historic operating results of the Company; nor is it meant to be predictive of potential future results. Adjusted EBITDA is not a measure of financial performance under IFRS and may not be comparable to other similarly titled measures for other companies. A reconciliation between the Company's net profit (loss) and Adjusted EBITDA is presented in the attached summary financial statements.
Because of these and other limitations, you should consider Adjusted EBITDA along with other IFRS-based financial performance measures, including net profit (loss) and our IFRS financial results.
About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS(TM)) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans, " "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words, and also includes any financial guidance and projections contained herein. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: risks relating to the Company's ability to consummate, finance and close proposed or potential investments, inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company's anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company's intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements.
Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's filings with the U.S. Securities and Exchange Commission.
Contacts:
BrainsWay:
Ido Marom
Chief Financial Officer
Ido.Marom@BrainsWay.com
Investors:
Brian Ritchie
LifeSci Advisors LLC
britchie@lifesciadvisors.com
BRAINSWAY LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
U.S. dollars in thousands
September 30, December 31,
2025 2024
ASSETS (Unaudited) (Audited)
---------------
Current Assets
Cash and cash
equivalents $ 70,458 $ 69,345
Restricted
cash 251 271
Trade
receivables,
net 5,129 4,596
Inventory 4,418 4,426
Other current
financial
assets 1,079 -
Other current
assets 1,598 1,032
82,933 79,670
-------------------------- ----------------------------
Non-Current
Assets
Investments in
financial
assets 12,567 -
System
components 2,912 1,707
Leased
systems, net 4,561 3,959
Other property
and
equipment,
net 787 752
Right-of-use
assets 5,757 5,530
Other
long-term
assets 3,545 2,698
30,129 14,646
-------------------------- ----------------------------
$ 113,062 $ 94,316
LIABILITIES AND
EQUITY
---------------
Current
Liabilities
Trade payables $ 2,791 $ 2,868
Deferred
revenues 13,615 4,434
Liability in
respect of
government
grants 2,488 1,293
Current
maturities of
lease
liabilities 1,043 824
Other accounts
payable 6,056 5,927
25,993 15,346
-------------------------- ----------------------------
Non-Current
Liabilities
Deferred
revenues 6,466 3,625
Liability in
respect of
government
grants 4,829 5,803
Lease
liabilities 5,709 4,800
Warrants
liability - 2,429
17,004 16,657
-------------------------- ----------------------------
Equity
Share capital 418 413
Share premium 159,873 157,597
Reserve for
share-based
payment 3,517 4,872
Warrants 2,126 -
Currency
Translation
Adjustments (2,188) (2,188)
Accumulated
deficit (93,681) (98,381)
70,065 62,313
-------------------------- ----------------------------
$ 113,062 $ 94,316
BRAINSWAY LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE PROFIT (LOSS)
U.S. dollars in thousands (except per share data)
For the three months ended
September 30, For the nine months ended September 30,
--------------------------------------------- --------------------------------------------
2025 2024 2025 2024
--------------------- ---------------------- --------------------- ---------------------
(Unaudited) (Unaudited)
Revenues $ 13,512 $ 10,502 $ 37,680 $ 29,602
Cost of revenues 3,353 2,781 9,412 7,532
Gross profit 10,159 7,721 28,268 22,070
--------------------- ---------------------- --------------------- ---------------------
Research and
development
expenses, net 2,396 1,809 7,072 5,146
Selling and
marketing
expenses 4,729 4,108 13,831 11,731
General and
administrative
expenses 1,781 1,523 4,958 4,233
Total operating
expenses 8,906 7,440 25,861 21,110
--------------------- ---------------------- --------------------- ---------------------
Operating
profit 1,253 281 2,407 960
Finance income 1,126 830 4,540 1,945
Finance Expense 571 374 1,778 1,182
Profit before
income taxes 1,808 737 5,169 1,723
Income taxes 242 75 469 350
--------------------- ---------------------- --------------------- ---------------------
Net profit and
total
comprehensive
profit $ 1,566 $ 662 $ 4,700 $ 1,373
================= === ================= ================= =================
Basic net income
per share $ 0.04 $ 0.02 $ 0.12 $ 0.04
================= === ================= ================= =================
Diluted net income
per share $ 0.04 $ 0.02 $ 0.11 $ 0.04
================= === ================= ================= =================
BRAINSWAY LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
U.S. dollars in thousands
For the three months ended
September 30, For the nine months ended September 30,
----------------------------------------------------- ------------------------------------------
2025 2024 2025 2024
---------------------------- ----------------------- ------------------- ---------------------
(Unaudited) (Unaudited)
Cash flows from
operating
activities:
Total
comprehensive
profit $ 1,566 $ 662 $ 4,700 $ 1,373
Adjustments to
reconcile net
profit to net
cash provided by
operating
activities:
Adjustments to
profit or loss
items:
Depreciation
and
amortization 179 188 550 308
Depreciation of
leased
systems 225 260 636 755
Impairment and
disposal of
inventory and
system
components 68 600 236 1,242
Finance income,
net (555) (456) (2,762) (763)
Cost of share
based payment 364 388 916 1,057
Income taxes 242 75 469 350
Total adjustments
to reconcile
profit 523 1,055 45 2,949
---------------------- ---- ---------------------- ------------------ ------------------
Changes in asset
and liability
items:
Decrease
(increase) in
inventory (115) (465) 310 (572)
Decrease
(increase) in
trade
receivables (1,246) 415 (419) 295
Decrease
(increase) in
other current
assets (796) 41 (532) 72
Increase
(decrease) in
trade
payables 1,551 (366) (139) 514
Increase
(decrease) in
other accounts
payable 1,330 456 492 (74)
Increase
(decrease) in
deferred
revenues (2,669) (52) 12,022 1,151
Total changes in
asset and
liability (1,945 ) 29 11,734 1,386
---------------------- ---- ---------------------- ------------------ ------------------
Cash paid and
received during
the period for:
Interest paid (34) (81) (88) (104)
Interest
received 1,274 613 3,022 2,194
Income taxes
paid 2 - (634) (994)
Total cash received
during the period 1,242 532 2,300 1,096
---------------------- ---- ---------------------- ------------------ ------------------
Net cash provided
by operating
activities: 1,386 2,278 18,779 6,804
---------------------- ---- ---------------------- ------------------ ------------------
Cash flows from
investing
activities:
Purchase of
property and
equipment and
system
components,
net (800) (1,300) (3,009) (2,871)
Withdrawal of
restricted
cash - - 20
Proceeds from
lease assets - - - 40
Purchase of
financial
assets
measured at
fair value (7,300) - (12,300) -
Proceeds from
short-term
bank deposits 10,000 - - 35,000
Investment in
short-term
bank deposits - - - -
Investment of
long-term
deposits, net (535) (34) (1,171) (15)
Net cash provided
by (used in)
investing
activities 1,365 (1,334) (16,460) 32,154
---------------------- ---- ---------------------- ------------------ ------------------
Cash flows from
financing
activities:
Repayment of
liability in
respect of
research and
development
grants - (572) (641) (1,104)
Exercise of
share options - - - 19
Repayment of
lease
liability (208) (126) (586) (237)
Net cash used in
financing
activities (208) (698) (1,227) (1,322)
---------------------- --- ---------------------- ------------------ ------------------
Exchange rate
differences on
cash and cash
equivalents 3 17 21 (29)
---------------------- ---- ---------------------- ------------------ ------------------
Increase in cash
and cash
equivalents 2,546 263 1,113 37,607
Cash and cash
equivalents at the
beginning of the
period 67,912 47,864 69,345 10,520
---------------------- ---- ---------------------- ------------------ ------------------
Cash and cash
equivalents at the
end of the period $ 70,458 $ 48,127 $ 70,458 $ 48,127
==== ================ ==== ==== ================ ==== ============ ==== ============
(a) Significant
non cash
transactions:
Change in
prepaid
expenses
recognized
with
corresponding
liability $ (1,631) $ - $ (144) $ -
==== ================ === ==== ================ ==== ============ ==== ============
Right-of-use
asset
recognized
with
corresponding
lease
liability $ 638 $ 5,469 $ 835 $ 5,650
==== ================ ==== ==== ================ ==== ============ ==== ============
BRAINSWAY LTD.
A reconciliation of Adjusted EBITDA to net profit,
the most directly comparable IFRS measure, is set
forth below:
U.S. dollars in thousands (except share and per share
data)
For the three months ended For the nine months ended
September 30, September 30,
------------------------------------------------- ------------------------------------------
2025 2024 2025 2024
------------------------ ----------------------- --------------- -------------------------
(Unaudited) (Unaudited)
Net profit and
total
comprehensive
profit $ 1,566 $ 662 $ 4,700 $ 1,373
Finance income,
net (555) (456) (2,762) (763)
Income taxes 242 75 469 350
Depreciation
and
amortization 179 188 550 308
Depreciation of
leased
systems 225 260 636 755
Cost of share
based payment 364 388 916 1,057
Restructuring
and litigation
Cost - - 258 -
Adjusted EBITDA $ 2,021 $ 1,117 $ 4,767 $ 3,080
--- ------------------ --- ----------------- --- --------- --- -----------------
(_____________________) (1 See Adjusted EBITDA details and reconciliation table in the appendix below.)
(END) Dow Jones Newswires
November 11, 2025 07:30 ET (12:30 GMT)
Comments